These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34868021)

  • 1. Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge.
    Senent Y; Inogés S; López-Díaz de Cerio A; Blanco A; Campo A; Carmona-Torre F; Sunsundegui P; González-Martín A; Ajona D; Okrój M; Prósper F; Pio R; Yuste JR; Tavira B
    Front Immunol; 2021; 12():767376. PubMed ID: 34868021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d.
    Kowalska D; Kuźniewska A; Senent Y; Tavira B; Inogés S; López-Díaz de Cerio A; Pio R; Okrój M; Yuste JR
    Front Immunol; 2022; 13():946522. PubMed ID: 36091057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients.
    Barratt-Due A; Pettersen K; Børresdatter-Dahl T; Holter JC; Grønli RH; Dyrhol-Riise AM; Lerum TV; Holten AR; Tonby K; Trøseid M; Skjønsberg OH; Granerud BK; Heggelund L; Kildal AB; Schjalm C; Aaløkken TM; Aukrust P; Ueland T; Mollnes TE; Halvorsen B;
    J Intern Med; 2024 Jul; 296(1):80-92. PubMed ID: 38539241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population.
    Cyprian FS; Suleman M; Abdelhafez I; Doudin A; Masud Danjuma M; Mir FA; Parray A; Yousaf Z; Siddiqui MYA; Abdelmajid A; Mulhim M; Al-Shokri S; Abukhattab M; Shaheen R; Elkord E; Al-Khal AL; Elzouki AN; Girardi G
    Front Immunol; 2021; 12():707159. PubMed ID: 34966381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement Anaphylatoxins and Inflammatory Cytokines as Prognostic Markers for COVID-19 Severity and In-Hospital Mortality.
    Alosaimi B; Mubarak A; Hamed ME; Almutairi AZ; Alrashed AA; AlJuryyan A; Enani M; Alenzi FQ; Alturaiki W
    Front Immunol; 2021; 12():668725. PubMed ID: 34276659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19.
    Apostolidis SA; Sarkar A; Giannini HM; Goel RR; Mathew D; Suzuki A; Baxter AE; Greenplate AR; Alanio C; Abdel-Hakeem M; Oldridge DA; Giles JR; Wu JE; Chen Z; Huang YJ; Belman J; Pattekar A; Manne S; Kuthuru O; Dougherty J; Weiderhold B; Weisman AR; Ittner CAG; Gouma S; Dunbar D; Frank I; Huang AC; Vella LA; ; Reilly JP; Hensley SE; Rauova L; Zhao L; Meyer NJ; Poncz M; Abrams CS; Wherry EJ
    Front Immunol; 2022; 13():834988. PubMed ID: 35309299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19.
    Valenti L; Griffini S; Lamorte G; Grovetti E; Uceda Renteria SC; Malvestiti F; Scudeller L; Bandera A; Peyvandi F; Prati D; Meroni P; Cugno M
    J Autoimmun; 2021 Feb; 117():102595. PubMed ID: 33453462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.
    Pons MJ; Ymaña B; Mayanga-Herrera A; Sáenz Y; Alvarez-Erviti L; Tapia-Rojas S; Gamarra R; Blanco AB; Moncunill G; Ugarte-Gil MF
    Front Immunol; 2021; 12():700921. PubMed ID: 34539631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study.
    Wargny M; Potier L; Gourdy P; Pichelin M; Amadou C; Benhamou PY; Bonnet JB; Bordier L; Bourron O; Chaumeil C; Chevalier N; Darmon P; Delenne B; Demarsy D; Dumas M; Dupuy O; Flaus-Furmaniuk A; Gautier JF; Guedj AM; Jeandidier N; Larger E; Le Berre JP; Lungo M; Montanier N; Moulin P; Plat F; Rigalleau V; Robert R; Seret-Bégué D; Sérusclat P; Smati S; Thébaut JF; Tramunt B; Vatier C; Velayoudom FL; Vergès B; Winiszewski P; Zabulon A; Gourraud PA; Roussel R; Cariou B; Hadjadj S;
    Diabetologia; 2021 Apr; 64(4):778-794. PubMed ID: 33599800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychological distress and health-related quality of life in patients after hospitalization during the COVID-19 pandemic: A single-center, observational study.
    Vlake JH; Wesselius S; van Genderen ME; van Bommel J; Boxma-de Klerk B; Wils EJ
    PLoS One; 2021; 16(8):e0255774. PubMed ID: 34379644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Objective evaluation and predictive value of olfactory dysfunction among patients hospitalized with COVID-19.
    Mangia LRL; Soares MB; de Souza TSC; De Masi RDJ; Scarabotto PC; Hamerschmidt R
    Auris Nasus Larynx; 2021 Aug; 48(4):770-776. PubMed ID: 33509637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce.
    Laudanski K; Okeke T; Siddiq K; Hajj J; Restrepo M; Gullipalli D; Song WC
    Sci Rep; 2022 Aug; 12(1):13658. PubMed ID: 35953544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics.
    Woodruff TM; Shukla AK
    Trends Immunol; 2020 Nov; 41(11):965-967. PubMed ID: 33023856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation and endothelial perturbation parallel COVID-19 severity and activity.
    Cugno M; Meroni PL; Gualtierotti R; Griffini S; Grovetti E; Torri A; Lonati P; Grossi C; Borghi MO; Novembrino C; Boscolo M; Uceda Renteria SC; Valenti L; Lamorte G; Manunta M; Prati D; Pesenti A; Blasi F; Costantino G; Gori A; Bandera A; Tedesco F; Peyvandi F
    J Autoimmun; 2021 Jan; 116():102560. PubMed ID: 33139116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy.
    Li J; Liu B
    Cytokine Growth Factor Rev; 2021 Apr; 58():75-81. PubMed ID: 33558131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China.
    Zhang X; Wang F; Shen Y; Zhang X; Cen Y; Wang B; Zhao S; Zhou Y; Hu B; Wang M; Liu Y; Miao H; Jones P; Ma X; He Y; Cao G; Cheng L; Li L
    JAMA Netw Open; 2021 Sep; 4(9):e2127403. PubMed ID: 34586367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid Hormone Levels During Hospital Admission Inform Disease Severity and Mortality in COVID-19 Patients.
    Beltrão FEL; Beltrão DCA; Carvalhal G; Beltrão FEL; Brito ADS; Capistrano KHRD; Bastos IHA; Hecht F; Daltro CHDC; Bianco AC; Gonçalves MDCR; Ramos HE
    Thyroid; 2021 Nov; 31(11):1639-1649. PubMed ID: 34314259
    [No Abstract]   [Full Text] [Related]  

  • 19. Mass Screening Is Associated with Low Rates of Acute Kidney Injury among COVID-19 Patients in Hong Kong.
    Chan KW; Hung IF; Tsang OT; Wu TC; Tso EY; Lung KC; Lam CM; Chan GC; Wong SS; Yu KY; Chan JW; Tang SC
    Am J Nephrol; 2021; 52(2):161-172. PubMed ID: 33765681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-month Follow-up Study of Survivors of Coronavirus Disease 2019 after Discharge.
    Liang L; Yang B; Jiang N; Fu W; He X; Zhou Y; Ma WL; Wang X
    J Korean Med Sci; 2020 Dec; 35(47):e418. PubMed ID: 33289374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.